Home » Stocks » CRXM

Gene Biotherapeutics Inc. (CRXM)

Stock Price: $0.0500 USD 0.0000 (0.00%)
Updated November 17, 2:24 PM EST - Market open

Stock Price Chart

Key Info

Market Cap 718,700
Revenue (ttm) n/a
Net Income (ttm) -3.85M
Shares Out 14.37M
EPS (ttm) -0.29
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 17
Last Price $0.0500
Previous Close $0.0500
Change ($) 0.0000
Change (%) 0.00%
Day's Open 0.0485
Day's Range 0.0457 - 0.0500
Day's Volume 109,507
52-Week Range 0.03 - 0.19

More Stats

Market Cap 718,700
Enterprise Value 542,333
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 14.37M
Float 12.77M
EPS (basic) -0.30
EPS (diluted) -0.29
FCF / Share -0.18
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 150,251
Short Ratio 1.03
Short % of Float 1.18%
Beta 1.60
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 3.36
Revenue n/a
Operating Income -3.07M
Net Income -3.85M
Free Cash Flow -2.55M
Net Cash 176,367
Net Cash / Share 0.01
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -758.60%
ROE n/a
ROIC 68.20%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$2.00*
Low
2.00
Current: $0.0500
High
2.00
Target: 2.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2016201520142013201220112010200920082007
Revenue---0.110.06-0.240.440.420.45
Revenue Growth---83.81%---45.05%6.72%-6.51%-
Gross Profit---0.040.01-0.240.440.420.45
Operating Income-2.84-3.11-3.58-6.91-8.29-7.42-6.77-8.71-17.15-17.44
Net Income-2.92-3.70-5.51-8.91-8.32-7.13-4.74-11.68-24.60-25.32
Shares Outstanding13.3312.8611.127.005.924.253.692.452.251.97
Earnings Per Share-0.28-0.34-0.50-1.33-1.41-1.60-1.20-4.80-11.00-12.80
Operating Cash Flow-2.02-1.05-2.62-6.03-9.21-7.67-7.41-11.61-16.61-21.36
Capital Expenditures-0.17---0.02-0.02--0.05--0.68-1.23
Free Cash Flow-2.20-1.05-2.62-6.05-9.23-7.68-7.47-11.61-17.30-22.58
Cash & Equivalents0.930.020.220.022.334.928.074.791.508.32
Total Debt--------4.044.72
Net Cash / Debt0.930.020.220.022.334.928.074.79-2.533.59
Assets1.110.040.752.797.817.509.515.4810.3016.93
Liabilities4.403.832.431.601.441.422.087.6311.058.50
Book Value-3.14--1.681.196.376.087.43-2.15-0.758.43
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Gene Biotherapeutics Inc.
Country United States
Employees 6
CEO Christopher J. Reinhard

Stock Information

Ticker Symbol CRXM
Stock Exchange US OTC
Sector Healthcare
Industry Biotechnology
Unique Identifier OTCMKTS: CRXM

Description

Gene Biotherapeutics manages a portfolio of medical technologies in the United States. It focuses on acquiring and developing gene-based therapeutics. The company, through its subsidiary, Angionetics, Inc., focuses on the clinical advancement and commercialization of Generx, an interventional cardiology, angiogenic gene therapy Phase 3 product candidate designed for the potential treatment of patients with refractory angina due to advanced coronary artery disease. It also holds royalties on the commercialization of Excellagen technology platform for advanced wound care in Eurasian countries. The company was formerly known as Taxus Cardium Pharmaceuticals Group, Inc. and changed its name to Gene Biotherapeutics, Inc. in January 2018. Gene Biotherapeutics, Inc. was founded in 2003 and is headquartered in San Diego, California.